Evidence map›Paper›PMID 34401876›Full record

ArticlebioRxiv : the preprint server for biology2021

Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles.

Zekun Mu, Kevin Wiehe, Kevin O Saunders, Rory Henderson, Derek W Cain, Robert Parks, Diana Martik, Katayoun Mansouri, Robert J Edwards, Amanda Newman and 16 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Zekun MuDepartment of Immunology, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Kevin O SaundersDepartment of Immunology, Duke University School of Medicine, Durham, NC, 27710, USA.
Rory HendersonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Derek W CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Diana MartikDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Katayoun MansouriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Robert J EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Amanda NewmanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Xiaozhi LuDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Shi-Mao XiaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
David MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Qifeng HanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Sravani VenkatayogiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Tyler EvangelousDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Yunfei WangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Wes RountreeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Ying TamAcuitas, Inc, Vancouver, Canada.
Christopher BarbosaAcuitas, Inc, Vancouver, Canada.
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Wilton B WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Norbert PardiPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Drew WeissmanPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Barton F HaynesDepartment of Immunology, Duke University School of Medicine, Durham, NC, 27710, USA.

Funding

Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4M
Project 2: Current Good Manufacture Practices (CGMP) Production of Nucleoside-Modified mRNAs Encoding HIV-1 EnvelopesU19AI135902 · NIAID · DUKE UNIVERSITY · PI PORTER, FREDERICK · 2018 to 2022
$19.8M
NIAID NIH HHS U19 AI135902NIAID NIH HHS UM1 AI144371
6 · The paper itself

Abstract

The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope (Env) trimer protein nanoparticles are superior immunogens compared to trimers alone for priming of broadly neutralizing antibody (bnAb) B cell lineages. The successful expression of complex multivalent nanoparticle immunogens with mRNAs has not been demonstrated. Here we show that mRNAs can encode antigenic Env trimers on ferritin nanoparticles that initiate bnAb precursor B cell expansion and induce serum autologous tier 2 neutralizing activity in bnAb precursor V

Indexed as

broadly neutralizing antibodiesHIV-1knock-in micelipid nanoparticlesmRNAmRNA-LNPvaccine

Identifiers

PMID34401876
PMCPMC8366792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.